News

iECURE is planning to submit an IND for GTP-506 in mid-2023.

Postmortem analyses revealed cell survival and GDNF production in transplanted areas.

Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has requested additional preclinical data from Beam Therapeutics on BEAM-201.

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).

The director of myeloma immunotherapy at University of Pennsylvania discussed cilta-cel's efficacy in lenalidomide-refractory multiple myeloma.

Precision Bio is taking a novel approach to gene editing to deploy a cure for patients with chronic hepatitis B.

The chief medical officer of Passage Bio discussed research needs in FTD.

The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.

The company has filed a patent for the new approach, which is designed to combat T-cell exhaustion.

The risk-benefit assessment determined that there are no significant safety concerns.

Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.

Lomecel-B is being evaluated in the phase 2 ELPISII study in children with hypoplastic left heart syndrome.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Updated data from the STAAR clinical trial were presented at the SSIEM Annual Meeting.

Researchers used novel functional MRI approaches to better measure the effects of gene therapy in children in current clinical trials.

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed the collaboration and research that went into developing beti-cel.

The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.

The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.

Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed the IND clearance of AVB-001 and the soon-to-initiate phase 1 trial.

The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.

Review top news and interview highlights from the week ending August 26, 2022.

The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.

Century Therapeutics will initiate the phase 1 ELiPSE-1 study imminently.

BioMarin plans to resubmit the biologics license application for val-rox to the FDA by the end of September 2022.

iECURE and the University of Pennsylvania Gene Therapy Program have collaborated to develop the GTP-506 program.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.